RADIUS GLOBAL INFRASTRUCTURE RADI 深 沪
等待开盘 08-07 09:30:00 美东时间
15.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 15.00
- 总市值 14.96亿
- 52周最高 15.18
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.97
- 委 比 0.00%
- 总股本 9971.70万
- 历史最高 18.79
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.57
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Praxis Announces Positive Results from RADIANT Study
An update from Praxis Precision Medicines ( ($PRAX) ) is now available. On Augu...
08-04 21:18
Guardant Health Study Shows Blood Test Detects Immunotherapy Response Early Across Multiple Cancer Types; Guardant Reveal Identified Non-Responders Up To 5 Months Before Standard Methods, Supporting Faster, More Effective Treatment Decisions In Advanced Cancer Care.
The first readout from Guardant's research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types and identified
07-29 20:09
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
Radiopharm Theranostics announced financial results for FY2025 and provided updates on its pipeline. Key highlights include: - On track to complete enrollment of first two cohorts for RAD204 at 60mCi dose. - Initiated Phase 1 HEAT trial for RAD202 targeting HER2-positive tumors. - FDA granted Fast Track Designation for RAD101 to assess brain metastases. - Secured supply agreements for key radioisotopes and expanded clinical trials. - Y...
07-29 11:30
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Radiopharm Theranostics has appointed Dr. Oliver Sartor, a leading medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board. Dr. Sartor, who serves at the Mayo Clinic, has contributed significantly to the field with over 500 publications and pivotal FDA-approved therapies. His expertise will support the company's oncology radiopharmaceutical pipeline development.
07-22 12:00
Radico Khaitan Schedules 41st AGM with E-Voting Facility
Radico Khaitan Limited ( ($IN:RADICO) ) has provided an update. Radico Khaitan ...
07-16 11:44
Radico Khaitan Emphasizes ESG in Latest Sustainability Report
The latest announcement is out from Radico Khaitan Limited ( ($IN:RADICO) ). Ra...
07-16 11:44
[ESP-IDF系列]使用ESP32驱动NRF24L01实现单点通讯
本文引用地址： 1 简介 最近想DIY一个四轴飞行器（简易的十字形遥控飞行器），也从晚上找了很多的视频和做了相关的简易研究（如果搞出来了...
06-29 15:24
Insulet To Showcase SECURE-T2D, RADIANT Clinical Trial Results And Real-World Omnipod 5 Data At ADA 2025
Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trialsReal-world evidence around glycemic outcomes from more than 23,000 people
06-19 18:16
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Radiopharm Theranostics has initiated its Phase 1 'HEAT' clinical trial for RAD202, a novel radiotherapeutic targeting HER2-positive solid tumors. The trial aims to evaluate safety, tolerability, optimal dosing for Phase 2, and early efficacy signals of 177Lu-RAD202 in advanced HER2-positive cancer patients. Previous studies demonstrated RAD202's safety and biodistribution. The trial, conducted across Australian centers, represents a significant ...
06-04 12:00
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
Radiopharm Theranostics announced preclinical data for their Lu177-B7H3-mAb RV01, showing favorable biodistribution, high tumor uptake, and a shorter half-life compared to traditional monoclonals, potentially reducing off-target exposure. The data support advancing RV01 to a first-in-human basket study in solid tumors, with an IND submission expected mid-2025 and Phase 1 initiation by year-end. RV01 targets the B7H3 receptor, highly expressed in ...
06-02 12:00
